Drinking Coffee Reduces Mortality in HIV/HCV Coinfection

Share this content:
Elevated coffee consumption at baseline was associated with a 50% reduced risk of all-cause mortality.
Elevated coffee consumption at baseline was associated with a 50% reduced risk of all-cause mortality.

HealthDay News — Drinking 3 or more cups of coffee per day halves all-cause mortality risk in patients co-infected with HIV/hepatitis C virus (HCV), according to a study published in the Journal of Hepatology.

Maria Patrizia Carrieri, from Aix Marseille University in France, and colleagues used data (both medical and psychosocial/behavioral) from a prospective cohort of patients co-infected with HIV/HCV to assess the effect of elevated coffee consumption (at least three cups per day) at baseline on all-cause mortality over a five-year follow-up period.

The researchers found that 77 deaths occurred over the study period among 1028 patients (mortality rate 1.64/100 person-years). 

HCV-related diseases (n = 33), cancers unrelated to AIDS/HCV (n = 9), and AIDS (n = 8) were the leading causes of death. At the first available visit, 26.6% of patients reported elevated coffee consumption. After adjustment for gender and psychosocial, behavioral, and clinical factors, elevated coffee consumption at baseline was associated with a 50% reduced risk of all-cause mortality (hazard ratio, 0.5).

"The benefits of coffee extracts and supplementing dietary intake with other anti-inflammatory compounds need to be evaluated in this population," conclude the authors.

Several authors disclosed financial ties to the pharmaceutical industry, which partially funded the study.

Reference

Carrieri MP, Protopopescu C, Marcellin F, et al. Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. J Hepatol. 2017 Dec;67(6):1157-1167.

You must be a registered member of Infectious Disease Advisor to post a comment.

Sign Up for Free e-newsletters